Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-671800. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 15/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-671800 SCHEMBL2788886 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| Bi-671800 SCHEMBL12415720 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| Bi-671800 SCHEMBL12415799 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| Bi-671800 SCHEMBL12415807 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| SCHEMBL12556770 | 0.94 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| SCHEMBL7688413 | 0.94 | PTGDR2 (0.88) | PTGDR2TBXA2RPTGDRNR1H4CTNNB1 | |
| SCHEMBL15750058 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRNR1H4CTNNB1 | |
| SCHEMBL1652340 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRNR1H4CTNNB1 | |
| Bi-671800 SCHEMBL12415784 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRNR1H4TRPV1 | |
| SCHEMBL12415827 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2024192765-A1 | FIRST IN CLASS USE OF THE CRTH2 ANTAGONIST IN TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND RELEVANT AUTOIMMUNE CNS DISORDERS | BROWN UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | claimed |
| US-8507005-B2 | Particulates of a CRTH2 antagonist | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| EP-2504319-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| US-8278310-B2 | Amine salts of a CRTH2 antagonist | ACTIMIS PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | claimed |
| US-20110294828-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | claimed |
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| WO-2011066176-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | claimed |
| JP-4671955-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-20110034482-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | GB005, INC. | 2011-02-10 | — | — | US | claimed |
| EP-1633726-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | claimed |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | GB005, INC. | 2010-12-23 | — | — | US | claimed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-2176240-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | Actimis Pharmaceuticals, Inc., (US) | 2010-04-21 | — | — | EP | claimed |
| WO-2008156781-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | ACTIMIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| JP-2006524645-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1633726-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | Actimis Pharmaceuticals, Inc., (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004096777-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | PTGDR2 78/4885TBXA2R 48/4885PTGDR 81/4885 |
| US-20110294828-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | SLC5A7, CHRNA5, CHKA | PTGDR2 1384/4885TBXA2R 609/4885PTGDR 736/4885 |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | HRH2, HRH1, CXCR2 | PTGDR2 73/4885TBXA2R 60/4885PTGDR 111/4885 |
| US-20110034482-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | HRH2, HRH1, HRH3 | PTGDR2 220/4885TBXA2R 53/4885PTGDR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.